After two years of under-performance shares of Novartis (NVS) could be poised for gains going...

After two years of under-performance shares of Novartis (NVS) could be poised for gains going into next year, according to Barron's. The report cites a promising pipeline of drugs, a 4% dividend and a below-market multiple, all of which should pay off handsomely over the near-term. Additionally, nearly 30% of the company's sales come from drugs that have come to market just since 2007, which Barron's attributes to the company's continued heavy investment into R&D, and is another element that adds to the stock's long-term attractiveness.

From other sites
Comments (4)
  • Ed's perspective
    , contributor
    Comments (262) | Send Message
    Haven't seen the article but it should also mention .... they OWN a very significant portion of ROCHE. This is a VERY dynamic company that will prosper for a long time.
    20 Nov 2012, 08:15 PM Reply Like
  • chopchop0
    , contributor
    Comments (4697) | Send Message
    Still kicking myself for missing out on opportunity to buy in low 50s back in June
    20 Nov 2012, 09:19 PM Reply Like
  • Vishal Manchanda
    , contributor
    Comments (50) | Send Message
    Besides a flourishing branded prescripiton drug business, being a conglomerate, the value of the different business embedded in this structure is not appreciated by the street. This article clearly brings out the value of NVS
    21 Nov 2012, 03:48 AM Reply Like
  • rushman35
    , contributor
    Comment (1) | Send Message
    why is the stock dropping ?????? if what you say is tru?
    21 Nov 2012, 04:16 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs